1. Life Sciences Panel Discussion
April 5-6, Fordham University
Stephane Drouin

2. UCB’s proposition Creating value for patients Focus on innovation
ADAPTABLE IP STRATEGIES
Focus on innovation
Engage in political and public debates
Evolve with new technologies
VALUE-BASED INNOVATION
Focus expertise
Engage partners and healthcare stakeholders
Open collaboration and Risk-sharing

3. Shifting the IP paradigm
UCB’s IP proposition
Pharmaceutical companies abuse IP to prolong exclusivity
Broad and non-transparent IP portfolios
A selective and measurable IP policy focused on core innovation to strengthen the acceptance of IP and our industry
A patent portfolio aligned with UCB’s PVS, protecting only UCB solutions that are valuable to patients and society
Public Perception
UCB

4. Innovation that makes a tangible difference to patients
Streamlining our patent portfolio has helped UCB to focus on CORE INNOVATION:
Innovation that makes a tangible difference to patients

5. UCB’s ‘core innovation’ proposition
What it means and how it differs
- 25 %
Pushing our company to find the right drug for the right patient
Patient-centric medicine providing access and sustainable healthcare meeting patient needs
Make the link between value we create and what we protect

6. …DELIVERING PATIENT SOLUTIONS IS.
Patents are not the goal…
…DELIVERING PATIENT SOLUTIONS IS.

8. Thanks!

9. Pat-INFORMED Database
Patent Information Initiative for Medicines (Pat-INFORMED)
Joint IFPMA and WIPO initiative announced at WIPO General Assembly (10/2017).
Aims to enhance the reputation of intellectual property as a foundation of global healthcare.
Welcomed by WHO, the Gates Foundation, the Medicines Patent Pool and many member states.
UCB and more than 20 other companies committed to make global patent information, similar to the US “Orange book”, on medicines available via Pat- INFORMED.
Initial database covers granted patents for small molecule products within oncology, hepatitis C, cardiovascular, HIV, diabetes, respiratory therapy areas, and any products on the WHO Essential Medicines List.